Metolazone Add-On Therapy in Heart Failure: A Cohort Study from Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF)

Table 3

Hazard ratio and odds ratio of death and re-hospitalization among study population according to different categories of diuretic usages.

Variables	Models	Diuretic agents		P
		Furosemide	Furosemide plus metolazone
Death	Univariate	1.00	0.86 (0.68–1.10)	0.241
	Multivariate	1.00	0.78 (0.59–1.03)	0.085
Re-hospitalization	Univariate	1.00	0.85 (0.66–1.10)	0.224
	Multivariate	1.00	0.80 (0.60–1.07)	0.135

Adjusted for age, sex, body mass index, ischemic heart disease, diabetes mellitus, hypertension, stroke, kidney diseases, chronic obstructive pulmonary disease, smoking, systolic blood pressure, diastolic blood pressure, heart rate, hemoglobin, sodium, potassium, blood urea nitrogen, creatinine, and discharged drug consumption (beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, digoxin, and nitrates).